Skip to main content
SpringerLink
Log in

Geschlechtsspezifische Unterschiede in der Pharmakotherapie

  • Chapter
Gender Medizin

Auszug

Geschlechtsspezifische Unterschiede in der Pharmakotherapie lassen sich auf verschiedenen Ebenen identifizieren. Manche Arzneistoffe werden bei Frauen langsamer oder schneller abgebaut als bei Männern, daher kann es zu einer stärkeren Wirkung — meist assoziiert mit einer höheren Nebenwirkungsrate — oder auch zu einer verringerten Wirkung kommen. Neben dem Arzneistoffmetabo-lismus sind auch Unterschiede in der Wirkweise, an Rezeptoren und Kanälen bekannt. Entscheidend ist, dass diese Fragestellung in Studien ausreichend Berücksichtigung findet und entsprechendes Wissen in Leitlinien und der Praxis umgesetzt wird.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aschhorn W, Whitworth A, Weiss EM, Marksteiner J (2006) Second-generation antipsychotics. Is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 29:578–598

    Google Scholar 

  2. Alexander KP, Chen AY, Newby K, et al (2006) Sex differences in major bleeding with glycoprotein llb/llla inhibitors.Circulation 114:1380–1387

    Article  PubMed  CAS  Google Scholar 

  3. Anastos K, Charney P, Charon RA, et al (1991) Hypertension in women: what is really known? The women’s caucus, working group on women’s health of the Society of General Internal Medicine. Ann Intern Med 115:287–293

    PubMed  CAS  Google Scholar 

  4. Berger J, Roncaglioni MC, Avanzini F, Pangrazzi I, To-gnoni G, Brown DL (2006) Aspirin for the primary prevention of cardiovascular events in women and men. JAMA 295:306–313

    Article  PubMed  CAS  Google Scholar 

  5. Blaustein MP, Robinson SW, Gottlieb SS, Balke CW, Hamlyn JM (2003) Sex, digitalis and the sodium pump. Mol Interv 3:68–72

    Article  PubMed  CAS  Google Scholar 

  6. Center for Drug Evaluation and Research (1993) Guidance for Industry. Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. Federal Register 58; No.139: 39406–39416

    Google Scholar 

  7. Cotreau MM, Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cyrochrome P450 3A substrates. Clin Pharmacokinet 44:33–60

    Article  PubMed  CAS  Google Scholar 

  8. Drici MD, Clement N (2001) Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24:575–585

    Article  PubMed  CAS  Google Scholar 

  9. Ebert SN, Liu XK, Woosley RL (1998) Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Women’s Health 7:547–557

    Article  CAS  Google Scholar 

  10. Evelyn B, Toigo T, Banks D, et al (2001) Women’s participation in clinical trials and gender-related labeling. A review of new molecular entities approved 1995-1999. FDA www.fda.gov/cder/ reports/womens_health/women_clin_trials.htm

    Google Scholar 

  11. Fleisch J, Fleisch MC, Thürmann PA (2005) Women in early-phase clinical drug trials: have things changed over the past 20 years? Clin Pharmacol Ther 78:445–452

    Article  PubMed  Google Scholar 

  12. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey JL, Bertschy G (2004) Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol 59:838–891

    Article  CAS  Google Scholar 

  13. Gex-Fabry M, Rudaz S, Balant-Gorgia AE, et al (2002) Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. Eur J Clin Pharmacol 58: 323–331

    Article  PubMed  CAS  Google Scholar 

  14. Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R (2002) Relationship between body composition parameters and fluorouracil pharmacokientics. Br J Clin Pharmacol 54:131–139

    Article  PubMed  CAS  Google Scholar 

  15. Haffner S, Lapp H, Thürmann PA (2002) Unerwünschte Arzneimittelwirkungen. Arzneimittelbedingte QT-Verlängerungen und Torsade-de-Pointes-Arrhythmien. Dtsch med Wschr 127: 1021–1024

    PubMed  CAS  Google Scholar 

  16. Hägg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169–173

    Article  PubMed  Google Scholar 

  17. Kaasinen V, Nurmi E, Brück A, et al (2001) Increased frontal [18F]fIuorodopa uptake in early Parkinson’s disease: sex differences in the prefrontal cortex. Brain 124:1125–1130

    Article  PubMed  CAS  Google Scholar 

  18. Keitt SK, Wagner KR, Marts SA (2003) Understanding the biology of sex and gender differences: using subgroup analyses and statistical design to detect sex differences in clinical trials. Medscape Gen Med 5; http://www.medscape.com/viewartide/455924

    Google Scholar 

  19. Kendall MJ, Quarterman CP, Jack DB, Beeley L (1982) Metoprolol pharmacokinetics and the oral contraceptive pill. Br J Clin Pharmacol 14:120–122

    PubMed  CAS  Google Scholar 

  20. Kornstein SG, Schatzberg AF, Thase ME, et al (2000) Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157:1445–1452

    Article  PubMed  CAS  Google Scholar 

  21. Kornstein SG, Sloan DM, Thase ME (2002) Gender-differences in depression and treatment response. Psychopharmacol Bull 36:99–112

    Google Scholar 

  22. Kubota K, Kubota N, Pearce GL, Inman WHW (1996) ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in Prescription-Event Monitoring. Eur J Clin Pharmacol 49:431–437

    Article  PubMed  CAS  Google Scholar 

  23. Laine K, Tybring G, Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharm Ther 68:151–159

    Article  CAS  Google Scholar 

  24. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED (2001) Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 286:708–713

    Article  PubMed  CAS  Google Scholar 

  25. Luchner A, Bröckel U, Muscholl M, et al (2002) Gender-specific differences of cardiac remodelling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res 53:720–727

    Article  PubMed  CAS  Google Scholar 

  26. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ (1999) Gender-related effects on meto-prolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharm Ther 66:594–601

    CAS  Google Scholar 

  27. Martenyi F, Dossenbach M, Mraz K, Metcalfe S (2001) Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 11:227–232

    Article  PubMed  CAS  Google Scholar 

  28. Martin R, Biswas PN, Freemantle SN, et al (1998) Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 46:505–511

    Article  PubMed  CAS  Google Scholar 

  29. Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329–342

    Article  PubMed  CAS  Google Scholar 

  30. Menguy R, Desbaillets L, Masters YF, Okabe S (1972) Evidence for a sex-linked difference in aspirin metabolism. Nature 239:102–103

    Article  PubMed  CAS  Google Scholar 

  31. Merkatz RB (1993) Women in clinical trials of new drugs. A change in the Food and Drug Administration policy. N Engl J Med 329:292–296

    Article  PubMed  CAS  Google Scholar 

  32. Morris ME, Lee H-J, Predko LM (2003) Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol Rev 55: 229–240

    Article  PubMed  CAS  Google Scholar 

  33. Nguyen TT, Mijares AH, Johnson CM, Jensen MD (1996) Postprandial lag and splanchnic fatty acid metabolism in nonobese men and women. Am J Physiol 271:E965–E972

    PubMed  CAS  Google Scholar 

  34. Nuutila P, Knuuti MJ, Maki M, et al (1995) Gender and insulin sensitivity in the heart and skeletal muscles. Studies using positron emission tomography. Diabetes 44:31–36

    Article  PubMed  CAS  Google Scholar 

  35. Parkinson A, Mudra DR, Johnson C, Dwyer A, Caroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.Toxicol Appl Pharmacol 199:193–209

    Article  PubMed  CAS  Google Scholar 

  36. Payami H, Zhu M, Montimurro J, Keefe R, McCulloch CC, Moses L (2005) One step closer to fixing association studies: evidence for age-and gender-specific allele frequency variations and deviations from Hardy-Weinberg expectations in controls. Hum Genet 118:322–330

    Article  PubMed  Google Scholar 

  37. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347:1403–1411

    Article  PubMed  CAS  Google Scholar 

  38. Ridker PM, Cook NR, Lee I-M, et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304

    Article  PubMed  CAS  Google Scholar 

  39. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL (2001) Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285: 1322–26

    Article  PubMed  CAS  Google Scholar 

  40. Schmiedl, S Szymanski J, Rottenkolber M, Drewelow B, Haase G, Hippius M, Reimann IR, Siegmund W, May K, Hasford J, Thürmann PA for the German Pharmacovigilance Study Group (2006) Drug-related hospital admissions with digitalis glycosides. Drug Saf 29:945 (abstr 63)

    Article  Google Scholar 

  41. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S (2001) Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 65:189–192

    PubMed  CAS  Google Scholar 

  42. Seeman MV (2004) Gender differences in prescribing of antipsychotic drugs. Am J Psychiatry 161: 1324–1333

    Article  PubMed  Google Scholar 

  43. Sloan JA, Goldberg RM, Sargent DJ, et al (2002) Women experience greater toxicity with fluorou-racil-based chemotherapy for colorectal cancer. J Clin Oncol 20:1491–1498

    Article  PubMed  CAS  Google Scholar 

  44. Spranger M, Aspey BS, Harrison MJG (1989) Sex difference in antithrombotic effect of aspirin. Stroke 20:34–37

    PubMed  CAS  Google Scholar 

  45. Tenter U, Thürmann PA (2006) References to sex-specific differences of drug effects in german SPCs for new entities from 1999 — 2004. Int J Clin Pharmacol Ther 44:531 (abstr.)

    Google Scholar 

  46. Thürmann PA (2005) Geschlechtsspezifische Unterschiede bei der Pharmakokinetik und-dynamik von Arzneimitteln. Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz 48:536–540

    Article  Google Scholar 

  47. Thürmann PA (2006) Geschlechtsspezifische Aspekte in der Pharmakotherapie: was ist gesichert? Z AIIg Med 82:380–384

    Article  Google Scholar 

  48. Thürmann PA, Haack S, Werner U, et al (2006) Tolerability of beta-blockers metabolized via cytochro-me P450 2D6 is sex-dependent. Clin Pharmacol Ther 80:551–553

    Article  PubMed  CAS  Google Scholar 

  49. Thürmann PA, Hompesch BC (1998) Influence of gender on the pharmacokinetics and pharmaco-dynamics of drugs. Int J Clin Pharmacol Ther 36: 586–590

    PubMed  Google Scholar 

  50. van Riemsdsjk MM, Sturkenboom MÜM, Ditters JM, et al (2004) Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 57:506–512

    Article  Google Scholar 

  51. Vidaver RM, Lafleur B, Jong C, Bradshaw R, Marts SA (2000) Women subjects in NIH-funded clinical research literature: lack of progress in both representation and analysis by sex. J Womens Health Gend Based Med 9:495–504

    Article  PubMed  CAS  Google Scholar 

  52. Walle T, Byington RP, Furberg CD, Mclntyre KM, Vokonas PS (1985) Biologic determinants of pro-pranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 38:509–518

    PubMed  CAS  Google Scholar 

  53. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, et al (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978–988

    PubMed  CAS  Google Scholar 

  54. Zappia M, Amnesi G, Nicoletti G, et al (2005) Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease. Arch Neurol 62:601–605

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HELIOS Klinikum Wuppertal Philipp Klee-Institut für Klinische Pharmakologie Heusnerstraße, 40, D-42283, Wuppertal, Germany

    Univ.-Prof. Dr. P. A. Thürmann

Authors
  1. Univ.-Prof. Dr. P. A. Thürmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Sozialmedizin, Medizinische Universität Wien, Österreich

    Anita Rieder

  2. Abteilung für Geschichte, Ethik und Philosophie der Medizin, Medizinische Hochschule Hannover, Deutschland

    Brigitte Lohff

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag/Wien

About this chapter

Cite this chapter

Thürmann, P.A. (2008). Geschlechtsspezifische Unterschiede in der Pharmakotherapie. In: Rieder, A., Lohff, B. (eds) Gender Medizin. Springer, Vienna. https://doi.org/10.1007/978-3-211-68290-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-68290-6_3

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-68289-0

  • Online ISBN: 978-3-211-68290-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation